StocksB › BTCY

Biotricity, Inc. (BTCY) — Earnings Call X-Ray

Our AI read all 14 of BTCY's earnings calls (2020–2024) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q2 2025 · sign up to see
Previous Call Grade
D
Q4 2024
Expected Move
🔒
next 45 days · members
Calls Analyzed
14
2020–2024
Avg Candor
5.4/9
evasion 2.6/9
Promotional ToneCritic AmmunitionFounder-LedVolume Step-UpEarly Product, Fast GrowthUnderused Fixed CostsMargins ExpandingDemand Accelerating

Call-by-call analysis

🔒 Q2 2025 earnings call 2024-11-15 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor /9
Specificity /9
Evasion /9
Stress /9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q2 2025 call grade is ready
The full 37-point AI read of BTCY's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

D Q4 2024 earnings call 2024-06-27

Management gave no formal guidance against accelerating demand and expanding margins. The delivery was rich in specifics, promotional in tone.

Demand: acceleratingMargins: expandingBacklog: growingPricing: stable 1 analysts · 4 questions
⚑ Critic ammunition⚑ Question left hanging✓ Volume step-up ahead✓ Early product, fast growth⚑ Reads rehearsedFounder-led
Candor 5/9
Specificity 7/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 7/9
Stress 2/9
Complexity 4/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q3 2024 earnings call 2024-02-21 move ±24.1%

Management held guidance steady against accelerating demand and expanding margins. The delivery was rich in specifics, promotional in tone.

Guidance: maintainedDemand: acceleratingMargins: expandingPricing: stableHeadcount: flatCapex: decreasing 2 analysts · 5 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth⚑ Reads rehearsed
Candor 6/9
Specificity 7/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 7/9
Stress 3/9
Complexity 4/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q2 2024 earnings call 2023-11-14

Management gave no formal guidance against steady demand and expanding margins. The delivery was rich in specifics, promotional in tone.

Demand: stableMargins: expandingPricing: stableHeadcount: cutting 1 analysts · 7 questions
⚑ Critic ammunition⚑ Question left hanging✓ Volume step-up ahead✓ Early product, fast growth⚑ Reads rehearsedFounder-led
Candor 6/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 7/9
Stress 3/9
Complexity 5/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q1 2024 earnings call 2023-08-15 move ±12.3%

Management gave no formal guidance against accelerating demand and expanding margins. The delivery was promotional in tone.

Demand: acceleratingMargins: expandingPricing: stableHeadcount: growing 1 analysts · 5 questions
⚑ Critic ammunition⚑ Question left hanging✓ Early product, fast growth⚑ Reads rehearsedFounder-ledDirection beats results
Candor 4/9
Specificity 6/9
Evasion 3/9
Confidence 8/9
Uncertainty 2/9
Promotion 7/9
Stress 2/9
Complexity 4/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q3 2023 earnings call 2023-02-14 move ±15.4%

Management gave no formal guidance against accelerating demand. The delivery was promotional in tone.

Demand: acceleratingMargins: stablePricing: stableHeadcount: growing 1 analysts · 5 questions
⚑ Critic ammunition⚑ Question left hanging✓ Volume step-up ahead✓ Early product, fast growth⚑ Reads rehearsedFounder-led
Candor 6/9
Specificity 6/9
Evasion 3/9
Confidence 8/9
Uncertainty 3/9
Promotion 7/9
Stress 2/9
Complexity 4/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q2 2023 earnings call 2022-11-14 move ±15.8%

Management held guidance steady against accelerating demand and contracting margins. The delivery was relaxed under questioning.

Guidance: maintainedDemand: acceleratingMargins: contractingPricing: stableHeadcount: growing 2 analysts · 7 questions
⚑ Critic ammunition⚑ Question left hanging✓ Volume step-up ahead✓ Early product, fast growth⚑ Reads rehearsedFounder-led
Candor 5/9
Specificity 6/9
Evasion 3/9
Confidence 8/9
Uncertainty 2/9
Promotion 6/9
Stress 1/9
Complexity 5/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q1 2023 earnings call 2022-08-15 move ±17.8%

Management gave no formal guidance against accelerating demand. The delivery was promotional in tone.

Demand: acceleratingMargins: stablePricing: stableHeadcount: growing 2 analysts · 6 questions
⚑ Critic ammunition⚑ Question left hanging✓ Volume step-up ahead✓ Early product, fast growth⚑ Reads rehearsedFounder-led
Candor 5/9
Specificity 6/9
Evasion 4/9
Confidence 8/9
Uncertainty 4/9
Promotion 7/9
Stress 3/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q3 2022 2022-02-15 D maintainedstableexpanding 6/9 2/9
Q2 2022 2021-11-09 D raisedacceleratingstable 5/9 3/9
Q1 2022 2021-08-17 C maintainedacceleratingexpanding 6/9 2/9
Q4 2021 2021-06-16 D raisedacceleratingexpanding 5/9 2/9
Q3 2021 2021-02-12 C raisedacceleratingunclear 6/9 3/9
Q2 2021 2020-11-19 D noneacceleratingunclear 5/9 3/9

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAC · AAC Holdings'AACAY · AAC Technologies HoldingAACG · ATA Creativity GlobalAADI · Aadi Bioscience, Inc.AALBF · Aalberts N.V.AAOI · Applied Optoelectronics,

BTBT   All “B” companies    BTDPF

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.